

Journal of Visualized Experiments

Alternative Surgical Approach for Middle Cerebral Artery Occlusion allowing Reperfusion via Common Carotid Artery Repair in Mice.

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58191R1
Full Title:	Alternative Surgical Approach for Middle Cerebral Artery Occlusion allowing Reperfusion via Common Carotid Artery Repair in Mice.
Keywords:	Neuroscience, Stroke, Transient MCAO, Brain Ischemia
Corresponding Author:	Claire Gibson UNITED KINGDOM
Corresponding Author's Institution:	
Corresponding Author E-Mail:	cg95@leicester.ac.uk
Order of Authors:	Melissa Trotman-Lucas Michael E Kelly Justyna Janus Claire Gibson
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the full address at which this article will be filmed .	University of Leicester, Leicester, United Kingdom



UNIVERSITY OF
LEICESTER

**Department of Neuroscience,
Psychology & Behaviour**

College of Medicine, Biological Sciences & Psychology
Maurice Shock Medical Sciences Building
PO Box 138
University Road
Leicester LE1 9HN
UK

T +44 (0)116 252 2922 (*Departmental Enqs*)
F +44 (0)116 252 5045

26th March 2018

Dear Editor-in-Chief,

We have submitted the following manuscript entitled 'Alternative surgical approach for middle cerebral artery occlusion allowing reperfusion via common carotid artery repair in mice'. This study describes an alternative surgical approach for inducing the commonly used experimental stroke model in mice which results in improved welfare and reduced variability within groups. The importance of this work is in demonstrating that reduced variability in animal stroke studies has the potential to increase animal wellbeing, reduce the number of animals used and potentially increase the efficacy of animal studies in detecting treatment effects.

The original modification and impact upon data has been published previously (see Trotman-Lucas et al. Dis Model Mech 2017; 10: 931-938, doi:10.1242/dmm.029108). The technique is technically challenging and therefore following discussion with Dr Nandita Singh, senior science editor for JoVE, we propose that this refined method would benefit from being published in JoVE's unique multimedia format. We hope you will agree that this is a timely manuscript and will appeal to a wide readership. I have included below the details of 6 suggested peer reviewers.

I can confirm that all authors have read and approved the submitted manuscript, the manuscript has not been submitted elsewhere nor published elsewhere in whole or in part, except as an abstract. In terms of author contributions - CG conceived the original study design. ML-T, JJ and MK performed the experiments and analysed the data. ML-T, MK and CG drafted and critically evaluated the manuscript. ML-T and CG will contribute to the video production.

Kind regards,

Dr Claire Gibson (on behalf of all authors)

Suggested peer reviewers

Dr Lawrence Moon
Institution: King's College, London
Email: lawrence.moon@kcl.ac.uk

Dr Raymond Wong
Institution: University of Manchester
Email: raymond.wong-2@manchester.ac.uk

Dr Andre Rex
Institution: Charite University, Berlin
Email: Andre.Rex@charite.de

Dr Chris McCabe

Institution: University of Glasgow
Email: Chris.McCabe@glasgow.ac.uk

Dr Brad Sutherland
Institution: University of Tasmania
Email: Brad.Sutherland@utas.edu.au

Dr Iqbal Sayeed
Institution: Emory University,
Email: isayeed@emory.edu

TITLE:

Middle Cerebral Artery Occlusion Allowing Reperfusion *via* Common Carotid Artery Repair in Mice

AUTHORS:

Melissa Trotman-Lucas¹, Michael E. Kelly², Justyna Janus², Claire L. Gibson¹

¹Department of Neuroscience, Psychology and Behaviour, University of Leicester, Leicester, United Kingdom

²Preclinical Imaging Facility, Core Biotechnology Services, University of Leicester, Leicester, United Kingdom

E-mail Addresses of the Co-Authors:

Melissa Trotman-Lucas (MT307@LE.AC.UK)

Michael E. Kelly (MK450@LE.AC.UK)

Justyna Janus (JJ167@LE.AC.UK)

Corresponding Author:

Claire L. Gibson (CG95@LE.AC.UK)

KEYWORDS:

Neuroscience, stroke, transient MCAO, brain, ischemia, middle cerebral artery

SHORT ABSTRACT:

Intraluminal filament occlusion of the middle cerebral artery is the most frequently used *in vivo* model of experimental stroke in rodents. An alternative surgical approach to allow common carotid artery repair is performed here, which allows the reperfusion of the common carotid artery and a full reperfusion to the middle cerebral artery territory.

LONG ABSTRACT:

The ischemic stroke is a major cause of adult long-term disability and death worldwide. The current treatments available are limited, with only tissue plasminogen activator (tPA) as an approved drug treatment to target ischemic strokes. Current research in the field of ischemic stroke focuses on better understanding the pathophysiology of stroke, to develop and investigate novel pharmaceutical targets. Reliable experimental stroke models are crucial for the progression of potential treatments. The middle cerebral artery occlusion (MCAO) model is clinically relevant and the most frequently used surgical model of ischemic stroke in rodents. However, the outcomes of this model, such as lesion volume, are associated with high levels of variability, particularly in mice. The alternative MCAO model described here allows the reperfusion of the common carotid artery (CCA) and the increased perfusion of the middle cerebral artery (MCA) territory, using a tissue pad with fibrinogen-based sealant to repair the vessel, and the improved welfare of the mice by avoiding external carotid artery (ECA) ligation. This reduces the reliance on the Circle of Willis, which is known to be highly anatomically variable in mice. Representative data show that using this alternative surgical approach decreases the variability in lesion volumes

between the traditional MCAO approach and the alternative approach described here.

INTRODUCTION:

A major cause of cerebral stroke is focal ischemia in the territory of the middle cerebral artery. Tissue plasminogen activator (tPA) is the only pharmacological treatment available with proven efficacy, despite numerous clinical drug trials targeted to ischemic stroke^{1,2}. However, due to safety concerns and a narrow therapeutic window (< 4.5 h), only ~15% of all stroke patients are eligible to receive tPA, and the recanalization rates can be < 50%^{3,4}.

Reproducible and clinically relevant animal models of stroke are considered essential to inform the development of new and potential stroke therapeutic treatments. However, due to concerns regarding consistency and variability in the outcomes with animal models, it remains important to refine existing *in vivo* models to improve the translation from preclinical studies to the clinic. The lack of translation from the preclinical experimental efficacy of potential treatments to clinical use is an ongoing concern for stroke research⁵. Reasons for failure of translation are likely to be multiple and may be related to, for example, the trial design, treatment delays, clinical stroke heterogeneity, and the limitations of the animal models used⁶. A key challenge for stroke research remains the development of safe and effective treatments.

Middle cerebral artery occlusion (MCAO) by intraluminal filament insertion is the most frequently used *in vivo* rodent model of experimental stroke. This model allows the restoration of the blood flow after an ischemia induction, mimicking the events that occur in human stroke⁷. However, in particular in mice, heterogeneous lesion volumes with varied standard deviations occur even though defined surgical protocols are applied⁸⁻¹⁰. It is typical to see a bimodal distribution of small striatal and large striato-cortical lesion volumes¹¹. To induce ischemia, the filament is typically inserted through an incision of the CCA or ECA which then remain permanently ligated¹². The permanent ligation of the CCA prevents the re-establishment of the blood flow into the internal carotid artery (ICA) and, subsequently, the MCA territory. This causes reperfusion to be reliant on the collateral supply within the Circle of Willis (CoW). The CoW structure has anatomical variability between individual animals, particularly in C57BL/6 mice—a strain typically used in *in vivo* stroke research¹³. An alternative method, of filament insertion through the ECA, does allow the continued perfusion through the CCA, but this method compromises the arterial supply to the ECA territory, which has been shown, in rats, to have a detrimental effect on the animal's well-being¹⁴.

The reliance on the CoW for collateral supply and reperfusion in the established MCAO model may, in part, account for the lesion volume variability following occlusion. We describe an alternative murine surgical procedure where ECA ligation is avoided and the CCA incision is repaired, thus permitting reperfusion through the CCA, independent of the CoW. The repair of the CCA incision has been previously shown in rats to result in a successful reperfusion through the CCA¹⁵. We have applied this approach successfully in mice¹¹ and report here the protocol which results in a reduced variability in lesion volume, the main outcome measure used in experimental stroke studies.

In this protocol, we demonstrate how to undertake MCAO through CCA vessel filament insertion followed by CCA vessel repair, which involves a tissue pad and sealant application to permit reperfusion.

PROTOCOL:

This protocol and the data reported were conducted in accordance with the UK Animals (Scientific Procedures) Act, 1986 (Project license 60/4315) and following institutional ethical approval. All experiments are reported in accordance with the Animal Research: Reporting of *In Vivo* Experiments (ARRIVE) guidelines¹⁶.

1. Preparation

1.1) Familiarize adult male C57BL/6 mice to post-operative care (*e.g.*, environment, bedding, recovery foods) at least 48 h before the surgery.

Note: Post-MCAO animals often have difficulty with eating and drinking following surgery.

1.1.1) To prevent excessive weight loss following surgery, acclimatize the animals to any post-MCAO diet by, for example, placing rehydration gel, gel food, and soaked/wet normal diet pellets directly onto the cage floor.

1.1.2) Change the cage bedding to post-operative bedding, such as white paper chip.

1.2) Sterilize all surgical tools before beginning the surgical set-up or procedures.

1.2.1) Do this by autoclaving the tools (with a minimum of 121 °C, 15 psi, for 15 min) or through the use of ethylene oxide (following the correct manufacturer's instructions, for 8 - 10 h).

1.2.2) Disinfect all surfaces prior to setting up the procedure. Cover all surfaces with sterile surgical drapes or autoclaved foil for items that require handling during the surgery. Use aseptic technique for the duration of the procedure.

Note: Autoclaved foil can be used to cover the instruments or equipment that need to be held during the surgery. Using sterile gloves and techniques, the foil can be applied and, then, the item can be placed into the sterile field. Following this, a sterile glove change will be required.

2. Middle Cerebral Artery Occlusion Surgery

2.1) Use adult male C57BL/6 mice weighing 24 - 31 g at the time of the surgery. Induce anesthesia using 5% isoflurane in 2 L/min of O₂, in a red plastic anesthesia chamber.

2.2) Following the induction, reduce the isoflurane to maintain an adequate anesthesia depth for the surgery (*e.g.*, 1.5% - 2% in 70% N₂O₂/30% O₂), delivered by face mask combined with a scavenger system to lower the surgeon's exposure to isoflurane.

Note: Nitrous oxide (N₂O₂) can be used in combination with oxygen (O₂) to reduce the required amount of isoflurane for an adequate anesthesia depth.

2.3) Administer systemic analgesia pre-operatively [carprofen, 10 mg/kg subcutaneous (sc.)] and local anesthesia to the incision site (bupivacaine, 2 mg/kg sc., diluted 1:10 in 0.9% saline) peri-operatively.

2.4) Administer fluids by intraperitoneal (ip.) injections of 200 µL of sterile prewarmed 0.9% NaCl solution pre-operatively.

2.5) Shave the fur of the right temporal region and ventral neck region using small hair clippers to expose the skin. Disinfect the surgical skin area, using a 5% chlorhexidine solution for 3 min. Apply ocular lubricant onto both eyes, to prevent them from drying during the surgery.

Note: If required for pulse oximetry readings to monitor blood oxygen saturation, heart rate, and breathing rate, use hair removal cream to clear the hind leg of hair. Applying the cream using clean cotton buds and, after the hair removal, wash the area with the dilute chlorhexidine solution. Perform this step in a pre-operative area to minimize the risk of loose fur contaminating the sterile surgical field.

2.6) Transfer the mouse to the surgical area and place it in the prone position on a homeothermic heat mat covered by a sterile drape. Maintain anesthesia *via* a nose cone. Insert a rectal probe to monitor the mouse's body temperature and maintain it at 37.0 ± 0.6 °C.

2.6.1) Prior to any surgical incisions, check the hind paw withdrawal reflex and blink reflex to confirm the anesthesia depth.

2.7) Attach a laser Doppler flowmetry (LDF) probe to record the blood flow to the MCA territory.

2.7.1) Using a dissection stereoscope, make an incision of < 1 cm at the midpoint between the right eye and ear on the exposed temporal skin using a No. 15 scalpel. Bluntly dissect the underlying tissue covering the skull, gently scraping this away from the bone and drying the surface with sterile cotton swabs.

Note: Care must be taken not to damage the temporalis muscle.

2.7.2) Take hold of the 0.7-mm, flexible single fiber-optic probe attached to the LDF monitor, cut its end using a sharp scalpel to gain a flat edge, push this through the donut-shaped probe holder, and place a small amount of optical matching gel at the end of the fiber.

2.7.3) Place a small amount of waterproof super-adhesive glue around the bottom edge of the probe holder; allow this to partially dry and become tacky.

2.7.4) Dry the skull above the temporal bone and place a small amount of topical tissue adhesive in a circle to the bone, just enough for the probe holder.

2.7.5) Place the probe holder, with the fiber optic probe already in place, on this area (6-mm lateral and 2-mm distal from the bregma).

2.7.6) Allow time for the glue to dry; once dry and attached, begin recording the LDF data.

2.8) Gently turn the animal over to a supine position, taking care to support the laser Doppler probe and prevent its detachment. Gently tape the two forepaws down with microporous medical tape, sliding a pair of cotton buds (or something similar, such as closed forceps) under the neck to lift the area and create tension. Cover the mouse with a sterile drape to maintain aseptic coverage.

2.9) Begin the dissection and exposure of the CCA.

2.9.1) Make a 1.5-cm midline incision on the exposed ventral neck using a No. 15 scalpel blade.

2.9.2) Using gentle blunt dissection techniques, gently retract the salivary glands to the sides, exposing the trachea.

2.9.3) Using blunt dissection, dissect the CCA free from the surrounding tissue and vagal nerve.

Note: Avoid touching the vagal nerve directly, as any damage to the vagal nerve can impair mobility, feeding, and breathing.

2.10) Pass two small (2-cm) sections of a non-dissolvable 6-0 suture below the CCA, dorsal to the vessel and ventral to the vagal nerve. Draw one silk tie closer to the surgeon and tie it loosely around the CCA (proximal tie). Loosely tie the second silk tie (distal tie) toward the bifurcation of the ICA/ECA.

2.11) To begin to isolate a section of the CCA, apply a microvascular clip just above the distal tie but not obstructing the bifurcation. Pull the proximal tie tight, while leaving the distal tie loosely tied. Using micro Vannas scissors, make a small hole into the CCA.

Note: The ECA must remain patent at all times. The CCA incision must be no more than 40% of the width of the vessel and in an easily accessible ventral position; this will play an important role in the vessel repair stage post-MCAO.

2.12) Insert a 7-0 silicone-coated monofilament into the CCA, advancing toward the microvascular clip.

Note: The filament size must be established based on the mouse's weight prior to the surgery; refer to the manufacturer's guidelines.

2.12.1) Tighten the distal tie, enough to fasten the filament into place without damaging it. Remove the microvascular clip using clip holders.

Note: No blood loss should be seen at this point. If there is a backflow of blood, the tie holding the filament is not tight enough.

2.13) Advance the filament into the ICA. Once the filament head has passed the distal tie surrounding it, tie the tie tighter to prevent any blood loss.

2.13.1) Ensure the filament remains within the ICA and does not pass into the pterygopalatine artery (PPA). Do this by slightly lifting and pulling the CCA, using one of the silk ties, to the outer side of the animal's body, and steer the filament to bend past the internally facing opening of the PPA.

Note: Once advanced to the MCA branch origin, a drop in the relative blood flow to the supplied territory will be visible on the LDF values; this confirms the filament placement.

2.14) Secure the filament in place with the distal silk tie, tying this tighter. Leave it in place for the duration of the occlusion time period.

Note: Dependent on individual protocols, the animal can be moved to a recovery cage, following wound suturing, to recover, or remain under anesthesia for the duration of the occlusion period. In the latter case, ensure the wound is prevented from drying out by using sterile prewarmed 0.9% NaCl saline.

3. Post-occlusion

3.1) At the end of the MCAO period, immediately retract the filament until the white filament head is clearly visible.

3.2) Loosen the distal CCA tie just enough to fully remove the filament head from the vessel, and then retie it to prevent blood loss.

3.3) Place one microvascular clip in a horizontal position toward the CCA bifurcation next to the distal tie and another microvascular clip below the distal CCA tie toward the surgeon.

Note: Ensure the vessel is far enough into the prongs of the clamp to prevent any slippage. The placement of the clips is essential to ensure clip removers easy access during later steps. The clips can be used to help lift the vessel to allow a better clearance and placement of the tissue patch, placing the clips horizontally across the surrounding muscles.

3.4) Carefully remove both silk ties using Dumont #5 forceps or micro Vannas scissors and dry the area using sterile cotton buds.

Note: Care must be taken not to cut through/into the vessel.

3.5) In a sterile Petri dish, add fibrinogen and thrombin sealant solutions 1 and 2 (see the **Table of Materials**), ensuring the two substances stay separate, ready for mixing later.

Note: Only very small volumes of the agents are required (< 0.25 mL each). Keeping the solutions separate prevents a premature reaction between the two constituents. Ensure the cap is replaced the same way as it was removed to prevent cross-contamination of the two syringes, which would cause the agent to react and set within the syringe. Prior to use, store the solutions at -20 °C. When required for the first surgery, thaw the sealant to room temperature. Do not refreeze the sealant; it must remain at room temperature and can be stored this way. The syringe can be used across multiple surgeries making it cost-effective; however, we recommend to not use the same vial for longer than 1 week to prevent contamination.

3.6) Use micro Vannas scissors to obtain a thin ventral slice of sternocleidomastoid muscle *via* a blunt dissection along the muscle to use for the tissue pad, ensuring the slice is no more than 1 mm thick and runs along the top fibers of the muscle.

Note: Do not cut through/across the muscle, as this will significantly impair its function. The tissue must be large enough to cover the CCA incision comfortably.

3.7) Using Dumont #5 forceps, take the tissue pad and mix the tissue evenly across the two fibrinogen and thrombin sealant solutions, forming a channel between the two reagents. Coagulation will occur quickly; as soon as coagulation begins, remove the tissue pad to the CCA incision. Place the tissue pad flat down with a medium firm pressure and open forceps.

3.7.1) Swiftly remove the top microvascular clip whilst still holding the tissue pad in place.

Note: This allows some backflow of blood to further activate the fibrinogen and thrombin sealant reagents. Just enough pressure is required to hold the pad in place but not to fully block the vessel.

3.7.2) Quickly remove the distal CCA vessel clip.

Note: The surgeon must still apply pressure to the fibrinogen- and thrombin-sealant-coated tissue pad.

3.7.3) Slowly alleviate the pressure from the tissue pad, allowing blood to flow under the incision area.

Note: In order to ensure the vessel becomes fully patent, the placement of the tissue pad and the removal of the microvascular clips must occur quickly to prevent the tissue pad from sealing to the inside of the CCA. However, if there is a small amount of blood leakage, re-place some light

pressure onto the tissue pad to allow further time for clot formation and sealing to occur. If the blood leakage is substantial or the tissue pad does not appear to be sealing, maintain pressure to prevent blood loss and replace both CCA microvascular clips to isolate the incision and prevent further blood loss.

3.8) In the event the tissue pad does not seal to the vessel, a second attempt can be made, following steps 3.3 - 3.7.3.

3.9) Once the vessel is sealed, suture the wound using dissolvable 6-0 sutures.

4. Post-operative Care

4.1) Place the animal into a prewarmed recovery cage (situated on a heated shelf/mat at 35 °C, or within a heated chamber).

Note: Researchers may prefer to use other temperatures and durations according to local practice.

4.2) Provide all animals with 200 µL of prewarmed 0.9% NaCl saline sc. immediately post-operation, at 4 h post-operation, and 2x daily for 72 h.

Note: The administration of prewarmed 0.9% NaCl is animal led. If more is required, more fluids can be administered to ensure a good recovery.

4.3) In the recovery cage, give the animals unrestricted access to soggy diet pellets, dry diet pellets, rehydration gel, and gel food, alongside *ad libitum* access to water.

4.4) Repeat the sc. carprofen injection at 24 h post-operation (see step 2.3).

Note: All animals received the same dose of carprofen; any neuroprotective effect is likely to be negligible.

4.5) At regular intervals for 48 h, perform post-op mouse grimace scoring¹⁷ to assess pain levels to aid the decision to administer further analgesia.

4.6) Weigh the animals immediately before surgery and then daily following the procedure. Perform daily observations and complete welfare sheets to monitor their food and water intake and clinical signs.

4.7) Undertake functional observations at 24 h and 48 h post-operation. Assess the mice on a focal deficit scale. Evaluate their body symmetry, compulsory circling, gait, 45° grid climbing, circling behavior, front limb asymmetry, and whisker touch response¹⁸⁻²⁰.

5. Magnetic Resonance Imaging and Image Processing

353
354 5.1) Measure the lesion volume (LV) using structural magnetic resonance imaging (MRI).

355
356 Note: Alternative methods, such as histological staining with triphenyltetrazolium chloride (TTC),
357 have previously been used and correlate to structural MRI data. However, this method can only
358 be used at the endpoint of a study and not longitudinally. Using longitudinal MRI scanning will
359 reduce the number of animals required for a study.

360
361 5.1.1) After 48 h, following the induction of the MCAO, anesthetize the mouse with isoflurane
362 (5% isoflurane in 1 L/min of O₂ for induction, 1.5% - 2% isoflurane for maintenance).

363
364 5.1.2) Transfer the mouse to the MRI cradle, place it on the respiration sensor for monitoring its
365 breathing rate, and implant the rectal temperature probe for monitoring its temperature during
366 the scanning. Place the 2-channel mouse-brain RF receive coil over the brain for a signal and place
367 the cradle in a 9.4 T horizontal bore scanner.

368
369 Note: Here, a volume coil with a 72-mm inner diameter was used for the RF transmission.

370
371 5.1.3) Acquire T2-weighted scans using a fast spin-echo sequence. Set the repetition time (TR) to
372 3,000 ms and the echo time (TE) to 40 ms. Use 18 mm x 18 mm as the field of view (FOV), and
373 obtain a 256 x 256 acquisition matrix with slices of 18 mm x 0.8 mm and three signal averages in
374 approximately 10 min.

375
376 5.1.4) Acquire diffusion tensor images (DTI) using a fast spin-echo sequence. Set the TR to 1,730
377 ms, the TE to 35 ms, the FOV to 20 mm x 20 mm, and obtain a 128 x 128 acquisition matrix with
378 slices of 16 mm x 1 mm, two signal averages, 14 diffusion encoding directions, and a maximum
379 *b*-value of 1,024 s/mm².

380
381 5.1.5) Measure the LV on the T2-weighted images using an image display and measuring software
382 package. Measure the lesioned area, collating the values together to calculate the total lesion
383 volume while taking into account the MRI slice thickness (set during the MRI scan).

384
385 5.1.6) Take into account any swelling and the percentage of area lesion volumes while measuring
386 the full contralateral and ipsilateral hemispheres. Correct for any brain swelling due to edema
387 using an indirect method to measure the lesion volume as described previously^{21,22}. Only include
388 slices that contain cortex tissue and not frontal lobe or cerebellum tissue according to a standard
389 mouse brain atlas to avoid overcorrection.

390
391 5.2) Measure the lesion diffusion parameters and obtain the core and penumbra regions of
392 interest.

393
394 5.2.1) Generate the apparent diffusion coefficient (ADC) and fractional anisotropy (FA) maps
395 from the diffusion tensor images using appropriate MRI analysis software.

5.2.2) Align the DTI images with the T2-weighted images using appropriate image analysis software capable of performing a linear registration of images. Following the registration, subtract the diffusion-weighted lesion masks (ischemic core) from the T2-weighted lesion masks (ischemic core and penumbra) to estimate the penumbra region. Apply the resultant masks (core and penumbra) to the ADC and FA maps to quantify the diffusion parameters within the core and penumbra.

5.2.3) Translate the ipsilateral core and the penumbra masks about the brain midline in order to obtain contralateral ADC and FA values for comparison.

REPRESENTATIVE RESULTS:

A total of 24 adult male C57BL/6 mice, weighing between 24 - 31 g at the time of surgery, were used in the study. One animal died following middle cerebral artery occlusion (MCAO) and one was excluded due to surgical complications. The data presented here are taken from a previously published work by the authors. These were used to illustrate the effect of vessel repair on MCAO outcomes¹¹. All data are expressed as the mean \pm standard deviation. The data were statistically assessed for normality using the D'Agostino-Pearson omnibus normality test. Parametric data were compared using Student's *t*-test (for two means) and one-way ANOVA with the Sidak test (multiple means). Non-parametric data were compared using the Mann-Whitney U test. The variability of the parametric data was assessed using an *F*-test, and non-parametric data variability was assessed using Levene's test.

Typically, in MCAO procedures, the occluding filament is inserted into the CCA and the ECA is ligated to prevent this filament from passing into the ECA rather than the ICA. An avoidance of ECA ligation and the addition of analgesia showed a trend toward reduced weight loss at 48 h post-MCAO, when compared to data from previous studies undertaken by the same surgeon for the same MCAO time using ECA ligation with no analgesia, whereas the LV appeared unaffected, see **Figure 1**.

Mice underwent a 60-min MCAO-induced ischemia followed by reperfusion with CCA vessel repair or with the typical ligation of the CCA approach. A schematic of the ligated and unligated repaired CCA is shown in **Figure 2**.

Laser Doppler flowmetry was used to confirm the blood flow perfusion in the territory of the MCA at MCAO, before and after the CCA vessel repair. **Figure 3** demonstrates that 5 min following the filament removal, the regional cerebral blood flow (rCBF) significantly increased in the brain region of the MCA. The perfusion was maintained up to the vessel repair, with an increase in the perfusion to the MCA territory shown following the CCA vessel repair, suggesting that the CCA repair allowed an increased blood perfusion to the ischemic territory compared to reliance on the Circle of Willis alone.

T2-weighted MRI was used to determine the total LV, and DTI scans were used to determine the core LV, 48 h after the MCAO. **Figure 4A** shows no significant difference in the total or core LV between the repair and ligated procedure groups. However, the data variability for both total

and core LV, as assessed using Lavene's test for non-parametric or the *F*-test for parametric data, was significantly reduced within the CCA repair group. The total LV was broken down into cortical and subcortical LV, as shown in **Figure 4B**. The cortical portion was significantly less variable in the CCA repair group, whereas the sub-cortical portion of the lesion was unaffected between the two procedural groups.

A power analysis indicated that fewer animals per treatment group would be required to demonstrate a 30% reduction in the LV following MCAO using CCA repair *versus* the typical CCA-ligated procedure, see **Table 1**. An assumption of power $1-\beta = 0.8$ and significance level $\alpha = 0.05$ and a prediction of 30% reduction in the LV between the hypothetical control and test groups were used for the power analysis. Furthermore, an equal variance was assumed between the groups. **Table 1** shows the number of animals required for the test and control groups when either the typical CCA-ligated method is used or the updated CCA repair method, as described here, is used. Note that the test group refers to a hypothetical treated group of animals and the control group refers to a hypothetical control group; both groups would undergo MCAO.

FIGURE and TABLE LEGENDS:

Figure 1: Combined analgesia treatment and the omission of ECA ligation on outcomes following MCAO. (A) Body weight, shown as a percentage of pre-MCAO weight, decreased the first 2 d following the MCAO for both groups. The ECA-unligated group (analgesia-treated with no ECA ligation at MCAO) showed a trend toward reduced weight loss on the second day following the MCAO. (B) This panel shows the lesion volume (mm^3) measured by standard triphenyltetrazolium chloride (TTC) staining 48 h after the MCAO. The data shown are the mean \pm standard deviation. ECA ligated: $n = 17$, ECA unligated: $n = 10$. This figure has been modified from Trotman-Lucas *et al.*¹¹.

Figure 2: Schematic showing the standard CCA method and the alternative CCA repair method following MCAO. (A) This schematic depicts a permanently ligated CCA using non-dissolvable sutures applied to either side of the CCA incision, resulting in the permanent ligation of the right CCA. (B) This schematic depicts the alternative CCA repair method. A small tissue pad coated with fibrinogen and thrombin sealant is used to cover the CCA incision, sealing it to allow the full perfusion of the right CCA. This figure has been modified from Trotman-Lucas *et al.*¹¹.

Figure 3: Regional cerebral blood flow (rCBF) parameters following MCAO. The rCBF changed 5 min after the MCAO filament removal for both the CCA-ligated and CCA-repaired groups (post-MCAO), relative to the rCBF measured during MCAO. This panel shows the rCBF data immediately before the CCA vessel repair (pre-repair) and 5 min following the CCA repair (post-repair). Significant increases in the rCBF are shown 5 min after the filament removal (post-MCAO) in both groups. An additional increase in the rCBF is shown following the CCA repair (post-repair) in the CCA repair group. No difference in the rCBF is shown between 5 min post-MCAO and pre-repair. The data shown are condensed from the analyzed time-course data reporting key time points, here as the mean \pm standard deviation. CCA ligated: $n = 10$, CCA repaired: $n = 10$; $**P < 0.01$, $***P < 0.001$, *ns*: non-significant. This figure has been modified from Trotman-Lucas *et al.*¹¹.

Figure 4: Analysis of the lesion volume obtained by MRI techniques. (A) This panel shows the lesion volume (LV; mm³) at 48 h following MCAO, the total LV taken from T2-weighted MRI images (Total LV), and the core LV taken from DTI scans and analysis (Core LV). Representative images show the total lesion volume from a T2 scan slice image with the DTI core lesion volume mask applied. The variability within the groups was significantly reduced for both the total LV ($P = 0.015$, CCA repair: $n = 10$, CCA ligated: $n = 10$, F -test) and the core LV ($P = 0.043$, CCA repair: $n = 9$, CCA ligated: $n = 6$, Lavené's test), assessed using an F -test for parametric data or Levene's test for non-parametric data. (B) This panel shows the LV at 48 h following MCAO, taken from T2-weighted MRI images and divided into cortical and subcortical lesion areas. The CCA repair significantly reduced the data variability ($P = 0.03$, F -test) in the cortical portion of the lesion, but no effect on the data variability in the subcortical portion of the lesion was shown. CCA repair: $n = 10$, CCA ligated: $n = 10$. The data shown are the mean \pm standard deviation. [#] $P < 0.05$ (F -test), [^] $P < 0.05$ (Lavené's test). This figure has been modified from Trotman-Lucas *et al.*¹¹.

Table 1: Representative power analysis comparing traditional CCA ligation with the alternative CCA repair method explained here. This table shows the power analysis conducted to calculate the anticipated group size required to detect a significant difference in the LV between a control group, the traditional or alternative (new) approach, and a test group (predicted). The table shows the group sizes as required if a power of 0.8 is assumed, a significance level of 0.05 is applied, and if the predicted test group shows a 30% difference in the LV compared to the control group. The table shows results for both MCAO approaches (the CCA-ligated and the CCA-repaired) to determine if there is a difference in the number of animals required to gain a 30% difference in the LV. For both methods, an equal variance is assumed between the test and the control group. This figure has been modified from Trotman-Lucas *et al.*¹¹.

DISCUSSION:

Filament induction of transient MCAO in rodents is the most frequently used experimental stroke model, as it allows reperfusion to the affected area, mimicking the occurrence of events following clinical ischemic stroke⁷. Reported here is an alternative surgical approach to the traditional method of filament-induced transient MCAO in mice. The alternative approach, involving analgesia treatment, ECA ligation avoidance, and CCA incision repair, results in a reduced LV variability when assessed using both MRI and histological staining methods¹¹.

Traditional approaches to induce MCAO largely rely on the transection, or at least ligation, of the ECA, which has been shown, in rats, to affect drinking behavior and an increase in body weight loss following the MCAO¹⁴. The protocol defined here, in mice, with the avoidance of ECA ligation and analgesia addition, suggested a reduction in body weight loss following the MCAO with no effect on the lesion volume. The use of analgesia is avoided, or at least not reported, in the majority of experimental stroke studies, due to possible confounding effects on the experimental outcome. However, avoiding analgesia completely is not always justified and there is a need to balance the welfare needs of the animals with the achievement of the scientific objectives.

Differences in animal size, strain, and cerebrovascular anatomy, in addition to filament size and

type variations, are all suggested to influence stroke outcomes^{23,24}. The alternative approach described here avoids the reliance on the CoW during reperfusion, thus reducing, at least in part, the variability seen between animals in lesion volume. CoW anatomy is highly variable in mice, in particular in the C57BL/6 strain, which is often used in experimental stroke studies. 90% of C57BL/6 mice have an incomplete CoW due to a varied posterior communicating artery (PcomA) patency, which may have an effect on the volume of ischemic damage due to the insufficient perfusion of structures outside of the MCA territory^{13,25}. Repairing the CCA in mice, as shown here, results in the re-establishment of blood flow *via* the CCA to the ischemic area, as previously described in rats¹⁵. The representative data here show that the repair of the CCA increases reperfusion, although the blood flow in the CCA was not directly measured. However, it is possible for the surgeon to visualize the CCA reperfuse with blood following the vessel repair, as it returns to a pulsing and full state all along the trunk, proximal and distal to the repair location. This visual confirmation, along with laser Doppler flowmetry readings of the ischemic area, can be used to confirm the successful repair of the vessel. The time between the tissue pad application and the removal of the vessel clip from the CCA can have an impact on the resulting patency of the CCA, as reducing the time between the tissue pad application and the clip removal will prevent the tissue pad from adhering to the opposite side of the CCA. Although technically challenging, the alternative MCAO procedure explained here does not require any additional skills than those required to perform the surgical induction of MCAO in mice.

Traditionally associated with a high variability in outcome measures, experimental stroke studies may have a tendency to be underpowered. Ethical and welfare requirements in combination with economic and practical concerns may contribute to studies being underpowered. By reducing the variability in outcome and, therefore, producing more consistent lesion outcomes across an experimental group, more effective power calculations can be performed with the ultimate aim of studies being appropriately powered.

In conclusion, this alternative CCA repair procedure, in mice, results in less variability in lesion volume following experimental stroke and enables smaller experimental groups to be required for testing a treatment effect when appropriate power calculations are used.

ACKNOWLEDGMENTS:

This work was funded by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs; NC/M000117/1 to CG). The authors thank the staff of the Division of Biomedical Services, University of Leicester, for their care of the experimental animals and Maria Viskaduraki for her statistical advice. The representative results are adapted with permission from Disease Models & Mechanisms¹¹.

DISCLOSURES:



The authors have nothing to disclose.


REFERENCES:


1. O'Collins, V. E. *et al.* 1,026 Experimental treatments in acute stroke. *Annals of Neurology*. **59** (3), 467-477 (2006).



2. Sutherland, B. A. *et al.* Neuroprotection for Ischaemic Stroke: Translation from the Bench to the Bedside. *International Journal of Stroke*. **7** (5), 407-418 (2012).
3. Reeves, M. J. *et al.* Acute Stroke Care in the US: Results from 4 Pilot Prototypes of the Paul Coverdell National Acute Stroke Registry. *Stroke*. **36** (6), 1232-1240 (2005).
4. Wardlaw, J. M., Murray, V., Berge, E., del Zoppo, G. J. Thrombolysis for acute ischaemic stroke. *Cochrane Database of Systematic Reviews*. (7), CD000213 (2014).
5. Pangalos, M. N., Schechter, L. E., Hurko, O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. *Nature Reviews Drug Discovery*. **6** (7), 521-532 (2007).
6. Hossmann, K. A. Pathophysiological basis of translational stroke research. *Folia Neuropathologica*. **47** (3), 213-227 (2009).
7. Ringelstein, E. B. *et al.* Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. *Neurology*. **42** (2), 289-289 (1992).
8. Carmichael, S. T. Rodent models of focal stroke: Size, mechanism, and purpose. *NeuroRX*. **2** (3), 396-409 (2005).
9. Dirnagl, U. Bench to Bedside: The Quest for Quality in Experimental Stroke Research. *Journal of Cerebral Blood Flow & Metabolism*. **26** (12), 1465-1478 (2006).
10. Ingberg, E., Dock, H., Theodorsson, E., Theodorsson, A., Ström, J. O. Method parameters' impact on mortality and variability in mouse stroke experiments: a meta-analysis. *Scientific Reports*. **6**, 21086 (2016).
11. Trotman-Lucas, M., Kelly, M. E., Janus, J., Fern, R., Gibson, C. L. An alternative surgical approach reduces variability following filament induction of experimental stroke in mice. *Disease Models & Mechanisms*. **10** (7), 931-938 (2017).
12. Macrae, I. M. Preclinical stroke research - advantages and disadvantages of the most common rodent models of focal ischaemia. *British Journal of Pharmacology*. **164** (4), 1062-1078 (2011).
13. McColl, B. W., Carswell, H. V., McCulloch, J., Horsburgh, K. Extension of cerebral hypoperfusion and ischaemic pathology beyond MCA territory after intraluminal filament occlusion in C57Bl/6J mice. *Brain Research*. **997** (1), 15-23 (2004).
14. Trueman, R. C. *et al.* A Critical Re-Examination of the Intraluminal Filament MCAO Model: Impact of External Carotid Artery Transection. *Translational Stroke Research*. **2** (4), 651-661 (2011).

15. Dittmar, M. S. *et al.* The role of ECA transection in the development of masticatory lesions in the MCAO filament model. *Experimental Neurology*. **195** (2), 372-378 (2005).
16. Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., Altman, D. G. Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research. *Plos Biology*. **8** (6), e1000412 (2010).
17. Langford, D. J. *et al.* Coding of facial expressions of pain in the laboratory mouse. *Nature Methods*. **7** (6), 447-479 (2010).
18. Orsini, F. *et al.* Targeting Mannose-Binding Lectin Confers Long-Lasting Protection With a Surprisingly Wide Therapeutic Window in Cerebral Ischemia. *Circulation*. **126** (12), 1484-1494 (2012).
19. Simoni, M. G. D. *et al.* Neuroprotection by Complement (C1) Inhibitor in Mouse Transient Brain Ischemia. *Journal of Cerebral Blood Flow & Metabolism*. **23** (2), 232-239 (2003).
20. Clark, W., Gunion-Rinker, L., Lessov, N., Hazel, K. Citicoline Treatment for Experimental Intracerebral Hemorrhage in Mice. *Stroke*. **29** (10), 2136-2140 (1998).
21. Lin, T. N., He, Y. Y., Wu, G., Khan, M., Hsu, C. Y. Effect of Brain Edema on Infarct Volume in a Focal Cerebral-Ischemia Model in Rats. *Stroke*. **24** (1), 117-121 (1993).
22. Loihl, A. K., Asensio, V., Campbell, I. L., Murphy, S. Expression of nitric oxide synthase (NOS)-2 following permanent focal ischemia and the role of nitric oxide in infarct generation in male, female and NOS-2 gene-deficient mice. *Brain Research*. **830** (1), 155-164 (1999).
23. Connolly, E. S., Winfree, C. J., Stern, D. M., Solomon, R. A., Pinsky, D. J. Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia. *Neurosurgery*. **38** (3), 523-531 (1996).
24. Barone, F. C., Knudsen, D. J., Nelson, A. H., Feuerstein, G. Z., Willette, R. N. Mouse Strain Differences in Susceptibility to Cerebral Ischemia are Related to Cerebral Vascular Anatomy. *Journal of Cerebral Blood Flow & Metabolism*. **13** (4), 683-692 (1993).
25. Kitagawa, K. *et al.* Cerebral Ischemia after Bilateral Carotid Artery Occlusion and Intraluminal Suture Occlusion in Mice: Evaluation of the Patency of the Posterior Communicating Artery. *Journal of Cerebral Blood Flow & Metabolism*. **18** (5), 570-579 (1998).









Approach	Lesion Volume	
	(LV; mm ³ ; mean ± s.d.)	Power
CCA Ligated (traditional approach)	94.08 ± 53.79	0.8
CCA Repaired (new approach)	51.73 ± 22.78	0.8

Significance Level	Anticiapted difference	Group size required
0.05	30%	$n = 58$
0.05	30%	$n = 35$

Name of Material/ Equipment	Company	Catalog Number	Comments/Description
0.7mm flexible single fibre optic probe	Moor Instruments, UK	P10d	Use with master probe code: VP10M200ST
7-0 silicone coated monofilament	Docol, USA	701956PKRe	Item dependent on animal size and weight - use manufacturer guidelines. Product code here was used for representative results shown in article.
9.4T Preclinical MRI system	Agilent Technologies, Santa Clara, California, USA	MY11520101	Equipped with gradient and RF coils suitable for mouse brain imaging
Animal monitoring and gating equipment	SA Instruments, Stony Brook, New York, USA	22124005	MRI compatible temperature and respiration monitoring
Bupivacaine	National Veterinary Services, Stoke-on-trent, UK	512345	Marcaine
C57BL/6 Mice	Charles River, Oxford, UK	B6JSIMA49D	
Carprofen	Norbrook Laboratories	143658	Carprieve 5% w/v Small animal solution for injection
Chlorhexidine 4% hand cleanser solution	VWR International Ltd, Lutterworth, UK	MOLN10008780	HibiScrub Antimicrobial hand cleanser, Molnlycke Health Care
Cotton buds	National Veterinary Services, Stoke-on-trent, UK	213512	Any plastic body, cotton bud tip are suitable once made sterile by autoclaving.
Dissecting stereoscope	Carl Zeiss	OPMI99	Resident piece of equipment. Any binocular dissecting stereoscope capable of x1-x5 magnification will be suitable.
dissolvable 6-0 sutures	National Veterinary Services, Stoke-on-trent, UK	9544	Absorbable Sutures Ethicon Coated Vicryl 6/0 (Ethicon code: W9981)
Donut probe holder	Moor Instruments, UK	PHDO	Probe holder for mouse, required to be used with single fibre optic probe when used with laser doppler flowmetry machine.

dumont #5 forceps	World Precision Instruments, Hertfordshire, UK	500342	
Fibrinogen and thrombin sealant	Baxter, Berkshire, UK	1502243	TISSEEL Ready to use solutions for Sealant 2ml
Gel food	Datesand group, Manchester, UK	72065022	Diet Gel Recovery
Image display and measuring software package	3D Slicer	https://www.slicer.org/	Version 4.0
Image display and measuring software package	NIH, Maryland, USA	https://imagej.nih.gov/ij/index.html	NIH/ImageJ
LDF monitor	Moor Instruments, UK	moorVMS-LDF	
micro vannas scissors	InterFocus Ltd, Linton, UK	15000-08	Other microvannas spring scissors can be used as an alternative, although fine tips are required.
Microvascular clip	World Precision Instruments, Hertfordshire, UK	15911	10 G Vessel Clip
microvascular clip holders	World Precision Instruments, Hertfordshire, UK	14189	
MRI acquisition and analysis software	Agilent Technologies, Santa Clara, California, USA	VnmrJ Version 4.2	Revision A
no. 15 scalpel	Scientific Laboratory Supplies, Nottingham, UK	INS4678	Sterile No15 Scalpel - manufactuer number P305. Other suppliers are available.
Non-dissolvable 6-0 suture	National Veterinary Services, Stoke-on-trent, UK	W529	Ethicon Mersilk Sutures
Ocular lubricant	National Veterinary Services, Stoke-on-trent, UK	847288	Lacrilube (5100G13)
Optical matching gel	Moor Instruments, UK	PMG	
Pulse Oximetry Reader	Starr Life Sciences Corp., Oakmont, PA, USA	MouseOx	MouseOx - rat & mouse pulse oximeter & physiological monitor Use with mouse thigh sensor.
Rehydration gel	Datesand group, Manchester, UK	70015022	HydroGel
Small hair clippers	vetproductsuk.com	HS61	Contura Cordless trimmer/clippers

Sterile 0.9 % NaCl Solution	VWR International Ltd, Lutterworth, UK	LOCA3528286	SODIUM CHLORIDE 0.9% W/V INTRAVENOUS INFUSION BP 500 ML IN ECOFLAC½ PLUS
sterile petri dish	VWR International Ltd, Lutterworth, UK	5168021	50mm sterile petri dish. Any brand is suitable. Minimum 50mm diameter is required.
Topical tissue adhesive	World Precision Instruments, Hertfordshire, UK	503763	GLUture topical Tissue Adhesive
Waterproof superglue	Loctite	Loctite Superglue Precision Max	Available at most hardware shops.
White paper chip	Datesand group, Manchester, UK	CS1BPB	Pure-O'Cel

612542.6 For questions, please contact us at submissions@jove.com or +1.617.945.9051.

of the Article, and in which the Author may or may not appear.

2. Background. The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JOVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. Grant of Rights in Article. In consideration of JOVE agreeing to publish the Article, the Author hereby grants to JOVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereof) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media, whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in Item 1 above, JOVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC license.

1. Defined Terms. As used in this Article and Video License Agreement, the following terms shall have the following meanings: "Agreement" means this Article and Video License Agreement; "Article" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "Author" means the author who is a signatory to this Agreement; "Collective Work" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "CRC License" means the Creative Commons Attribution 3.0 Agreement (also known as CC-BY), the terms and conditions of which can be found at <http://creativecommons.org/licenses/by/3.0/us/legalcode>; "Derivative Work" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "Institution" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "JOVE" means MyJOVE Corporation, a Massachusetts corporation and the publisher of the Journal of Visualized Experiments; "Materials" means the Article and / or the Video; "Parties" means the Author and JOVE; "Video" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JOVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

ARTICLE AND VIDEO LICENSE AGREEMENT

Item 2: Please select one of the following items:

☒ The Author is NOT a United States government employee.

☐ The Author is a United States government employee, and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:


☐ Standard Access

☒ Open Access

Title of Article: *Alternative surgical approach for middle cerebral artery occlusion allows reperfusion via common carotid artery*

Author(s): *Matsumoto - Kiyoshi M, Kelly M, Janus S, Gibson CC*

ARTICLE AND VIDEO LICENSE AGREEMENT - UK



4. **Retention of Rights in Article:** Notwithstanding the exclusive license granted to JOVE in Section 3 above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the institution's website or the Author's personal website, in each case provided that a link to the Article on the JOVE website is provided and notice of JOVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video - Standard Access:** This Section 5 applies if the "Standard Access" box has been checked in Item 1 above or if no box has been checked in Item 1 above. In consideration of JOVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, subject to Section 7 below, JOVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JOVE.

6. **Grant of Rights in Video - Open Access:** This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JOVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JOVE, subject to Section 7 below, (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats.


7. **Government Employees:** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in Item 2 above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be null and void.

8. **Protection of the work:** The Author(s) authorize JOVE to take steps in the Author(s) name and on their behalf if JOVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality:** The Author hereby grants JOVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties:** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JOVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation, all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JOVE Discretion:** If the Author requests the assistance of JOVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JOVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JOVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JOVE reserves the right, in its absolute and sole



decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include Jove's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JOVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JOVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JOVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JOVE and shall inure to the benefit of any of JOVE's successors and assigns. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

discretion and without giving any reason therefor, to accept or decline any work submitted to JOVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the video, whether actually published or not. JOVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JOVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JOVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JOVE, making of videos by JOVE, or publication in JOVE or elsewhere by JOVE. The Author shall be responsible for, and shall hold JOVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JOVE its employees, agents or independent contractors. All sterilization, cleanliness or

CORRESPONDING AUTHOR

Name: Claire L. Gibson
 Department: Neuroscience, Psychology and Behaviour
 Institution: University of Leicester
 Title: Dr.
 Signature: [Handwritten Signature]
 Date: 11.6.18

Please submit a signed and dated copy of this license by one of the following three methods:

1. Upload an electronic version on the JOVE submission site
 2. Fax the document to +1.866.381.2236
 3. Mail the document to JOVE / Attn: JOVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140
- For questions, please contact us at submissions@jove.com or +1.617.945.9051.

From: em.jove.f367.5ad79a.1417bba7@editorialmanager.com
[<mailto:em.jove.f367.5ad79a.1417bba7@editorialmanager.com>] **On Behalf Of** Alisha DSouza

Sent: 27 April 2018 22:24

To: Gibson, Claire L. (Dr.) <cg95@leicester.ac.uk>

Subject: Revisions required for your JoVE submission JoVE58191

CC: mt307@le.ac.uk, mk450@le.ac.uk, jj167@le.ac.uk

Dear Dr. Gibson,

Your manuscript, JoVE58191 Alternative Surgical Approach for Middle Cerebral Artery Occlusion allowing Reperfusion via Common Carotid Artery Repair in Mice., has been editorially and peer reviewed, and the following comments need to be addressed. Note that editorial comments address both requirements for video production and formatting of the article for publication. Please track the changes within the manuscript to identify all of the edits.

After revising and uploading your submission, please also upload a separate rebuttal document that addresses each of the editorial and peer review comments individually. Please submit each figure as a vector image file to ensure high resolution throughout production: (.svg, .eps, .ai). If submitting as a .tif or .psd, please ensure that the image is 1920 pixels x 1080 pixels or 300 dpi.

Your revision is due by **May 18, 2018**.

To submit a revision, go to the [JoVE submission site](#) and log in as an author. You will find your submission under the heading "Submission Needing Revision".

Best,

Alisha DSouza, Ph.D.

Senior Review Editor

[JoVE](#)

617.674.1888

Follow us: [Facebook](#) | [Twitter](#) | [LinkedIn](#)

[About JoVE](#)

Editorial comments:

The manuscript has been modified to include line numbers and minor formatting changes. The updated manuscript **58191_R0.docx** is located in your Editorial Manager account. In the revised PDF submission, there is a hyperlink to download the .docx file. **Please download the .docx file and use this updated version for future revisions.** The file is also attached.

You will find Editorial comments and Peer-Review comments listed below. Please read this entire email before making edits to your manuscript.

NOTE: Please include a line-by-line response to each of the editorial and reviewer comments in the form of a letter along with the resubmission.

Changes recommended by the JoVE Scientific Review Editor:

- Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammatical errors.

- **Protocol Language:** Please ensure that ALL text in the protocol section is written in the imperative voice/tense as if you are telling someone how to do the technique (i.e. "Do this", "Measure that" etc.) Any text that cannot be written in the imperative tense may be added as a "Note", however, notes should be used sparingly and actions should be described in the imperative tense wherever possible.

1) Examples not in imperative tense: 1.1.2, 2.11.1, 2.12, 2.13, 4.3

Response: These have been amended appropriately.

- **Protocol Detail:** Please note that your protocol will be used to generate the script for the video, and must contain everything that you would like shown in the video. There should be enough detail in each step to supplement the actions seen in the video so that viewers can easily replicate the protocol.

Response: We are satisfied with the amount of detail given.

- **Protocol Highlight:** After you have made all of the recommended changes to your protocol (listed above), please re-evaluate the length of your protocol section. There is a 10-page limit for the protocol text, and a 3- page limit for filmable content. If your protocol is longer than 3 pages, please highlight ~2.5 pages or less of text (which includes headings and spaces) in yellow, to identify which steps should be visualized to tell the most cohesive story of your protocol steps.

1) The highlighting must include all relevant details that are required to perform the step. For example, if step 2.5 is highlighted for filming and the details of how to perform the step are given in steps 2.5.1 and 2.5.2, then the sub-steps where the details are provided must be included in the highlighting.

2) The highlighted steps should form a cohesive narrative, that is, there must be a logical flow from one highlighted step to the next.

3) Please highlight complete sentences (not parts of sentences). Include sub-headings and spaces when calculating the final highlighted length.

4) Notes, anesthesia, and euthanasia cannot be filmed and should be excluded from highlighting.

Response: Completed.

- Please define all abbreviations at first use.

Response: Completed.

- Please use standard abbreviations and symbols for SI Units such as μL , mL, L, etc., and abbreviations for non-SI units such as h, min, s for time units. Please use a single space between the numerical value and unit.

Response: Completed.

- If your figures and tables are original and not published previously or you have already obtained figure permissions, please ignore this comment. If you are re-using figures from a previous publication, you must obtain explicit permission to re-use the figure from the previous publisher (this can be in the form of a letter from an editor or a link to the editorial policies that allows you to re-publish the figure). Please upload the text of the re-print permission (may be copied and pasted from an email/website) as a Word document to the Editorial Manager site in the "Supplemental files (as requested by JoVE)" section. Please also cite the figure appropriately in the figure legend, i.e. "This figure has been modified from [citation]."

Response: provided and completed.

Comments from Peer-Reviewers:

Reviewers' comments:

Reviewer #1:

Manuscript Summary:

This is a nicely written paper describing the alternative approach and modifications to animal model of stroke by intraluminal suture method. The new procedures are certainly refinement of existing transient MCAO model and will benefit the stroke research community working with animal model of stroke. Following the new procedures will reduce the mortality and variability encountered with existing transient stroke model. The methods are described in detail and easy to follow steps.

Major Concerns:

None

Minor Concerns:

I have following suggestions to improve the manuscript:

1. Abstract only states using alternative surgical approach will decrease the variabilities in outcome measures. In the abstract it would be nice to mention briefly about the specific alternative approaches (use of tissue pads sealing, avoidance of ECA ligations).

Response: This detail has been added.

2. Providing a better description and precautions (thawing, freezing, shelf life) of Baxter sealant either in section 3.5 or table will be helpful. More researchers will adopt the method if it is made clear that price and effort for adopting this technique is comparatively low.

Response: This detail has been added.

3. It appears that LD-CBF measurements (figure 3) in pre-repair (CCA repaired) show less variability than post repair. The CBF increase in post repair group is more compared to pre repair showing increased perfusion of the MCA territory. It would be helpful to compare pre and post repair reperfusion CBF for the significance. Reperfusion CBF level will certainly have an impact on the outcome measures. This is very interesting finding and should be further highlighted and discussed.

Response: It does appear, in Figure 3, that the LD-CBF measurements show less variability in pre-repair than post repair. In terms of significance, as shown on the graph, the LD-CBF response is significantly (***) $P < 0.001$ increased at post-repair compared to pre-repair.

4. It would be helpful for the new investigator to include an additional panel in figure 2 showing the anatomy of the arteries (circle of Willis, ECA, ICA, incision site etc). This can be reproduced from other publications.

Response: We have not added this figure because, as the reviewer suggests, this kind of figure is available in a number of other publications. In addition, this paper is probably aimed more at those with some prior experience of MCAO rather than a complete novice.

5. It would be nice to include discussions on the need for comparing the new approach on long term general wellbeing, functional outcome measures and extended patency of the sealed CCA. Also, it would be nice to compare the effect of ECA ligation on behavioral measures such as tongue protrusion tests affecting the feeding behavior.

Response: The authors agree that it would be good to study the effects of long term behavioural responses following this refined vessel repair. This is outwith the scope of the current publication which is focused on detailing the methods associated with the vessel repair procedure.

This is an important, timely and nicely done study. Congratulations.

Reviewer #2:**Manuscript Summary:**

The current MS describes the development of a method for the refinement of the operation technique of the middle cerebral artery occlusion (MCAO) by intraluminal filament insertion to mimic human ischemic stroke. There is some novelty to this method, in that it differs from well-established operation techniques not restoring blood-flow in the brain, and might work as a refinement to the MCAO surgery.

The authors should be applauded for tackling the restoration of blood-flow after occlusion of the MCA. In general, the manuscript in general is well written. However, I suggest some minor changes addressing the following problems:

Major Concerns:

The authors describe short-term macroscopic effects only (MRI- Measurements) no improvement in functional outcome was assessed. This would improve the ms. and validate the CCA-repaired-method.

Response: The authors agree that it would be good to study the effects of long term behavioural responses following this refined vessel repair. This is outwith the scope of the current publication which is focused on detailing the methods associated with the vessel repair procedure.

Minor Concerns:**Procedure:**

The authors allow local deviations from their protocol (page 8, line 315-316. I suggest that the authors allow the use of local protocols prior the actual MCAO-surgery (lines 126-213).

Response: There will inevitably be some local variation in acclimatisation protocols but where feasible these should be as consistent as possible.

Representative results:

1. The authors state "Typically in MCAO procedures the occluding filament is inserted into the CCA and the ECA is ligated to prevent this filament passing into the ECA rather than the ICA. Avoidance of ECA ligation and addition of analgesia showed a trend towards improved weight loss at 48 hours post-MCAO, when compared to data from previous studies undertaken by the same surgeon for the same MCAO time using ECA ligation with no analgesia whereas lesion volume (LV) appeared unaffected, see Figure 1." Could the authors discriminate between the possible impact of analgesia and/or saving the ECA?

Response: It is not possible to distinguish this statistically as both variables (i.e. ECA ligation avoidance and analgesia addition) were implemented at the same time.

2. The phrase "a trend towards improved weight loss" might be misleading. As far as I understand, an improved weight loss means losing more weight, which would be contra productive.

Response: This has been changed to a trend towards reduced weight loss.

3. Page 10, para 6, lines 397-399 should be moved to the methods section.

Response: Given the format of this paper it appears clearer to leave this in the results section as it shows diagrammatically what is achieved.

4. Regarding the figures no description of the statistical tests used are given.

Response: Some text has now been added to the start of the results section.

5. Did the authors use Levene Test for Equality of Variances?

Response: Yes, the Levene's test for equality of variances was used (spelling mistake of Lavene has been corrected in manuscript).

Discussion:

2nd paragraph, lines 490-497. What is the significance of these results, regarding the "repaired CCA"-method? Could the authors discuss that or omit this paragraph, since no experimental data are given.

Response: We have omitted this paragraph and the references renumbered accordingly.

Figures:

It might be better, if you would use the identical sorting of data sets on the x-axis, like CCA ligated on the left and CCA repaired on the right consistently to make reading the figures easier.

Response: This refers to figures 3 and 4 which are taken directly (as referenced) from our previous publication. Within each figure set the data is presented in consistent manner.

Considering that, I believe that the manuscript needs a revision before it can be considered for publication. After this is done, I would be glad to review the paper again and discuss the procedure.

From: permissions <permissions@biologists.com>
Date: Friday, 23 March 2018 at 08:27
To: "cg95@le.ac.uk" <cg95@leicester.ac.uk>
Cc: permissions <permissions@biologists.com>
Subject: RE: Enquiry

Dear Claire,

Thank you for your enquiry. As an author of the original work you are free to reproduce figures without permission, I normally suggest courtesy contact with any co-authors to avoid any potential future conflict.

The acknowledgement should state "reproduced / adapted with permission" and give the source journal name - the acknowledgement should either provide full citation details or refer to the relevant citation in the article reference list - the full citation details should include authors, journal, year, volume, issue and page citation.

Where appearing online or in other electronic media, a link should be provided to the original article (e.g. via DOI).

Development: <http://www.biologists.com/development>
Disease Models & Mechanisms: <http://www.biologists.com/disease-models-mechanisms>
Journal of Cell Science: <http://www.biologists.com/journal-of-cell-science>
Journal of Experimental Biology: <http://www.biologists.com/journal-of-experimental-biology>
Biology Open <http://www.biologists.com/biology-open>

We wish you the best of luck with your project.

Kind regards

Richard
Richard Grove
Commercial Manager
The Company of Biologists Ltd
Bidder Building, Station Road, Histon, Cambridge, CB24 9LF, UK
T: +44 (0) 1223 653 874 richard.grove@biologists.com | www.biologists.com